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ABSTRACT 
Sialorrhoea is a common and problematic symptom arising from a range of neurological 
conditions associated with bulbar or facial muscle dysfunction. As well as the physical 
complications of drooling such as peri-oral chapping, there can be significant 
embarrassment, which can lead to social isolation and may ƐŝŐŶŝĨŝĐĂŶƚůǇĂĨĨĞĐƚĂƉĂƚŝĞŶƚ ?Ɛ
quality of life. Thicker, tenacious oral and pharyngeal secretions may be a consequence of 
the drying management approach to sialorrohoea. Co-existence of these types of secretion 
problems can complicate the management of oral secretions and a balance must be struck 
to achieve an acceptable outcome. 
There are a variety of management approaches for sialorrhoea in neurological diseases, 
which vary depending on the underlying pathology and severity of symptoms. Interventions 
include anticholinergic drugs, salivary gland targeted radiotherapy, salivary gland botulinum 
toxin, and surgical approaches. The management of thick secretions consists of 
predominantly conservative measures such as using pineapple juice as a lytic agent, cough 
assist, saline nebulisers and suctioning. These patients may also benefit from mucolytic 
drugs such as carbocisteine. Currently there is a lack of evidence, and practice varies, but 
management of sialorrhoea should be part of the multi-disciplinary approach needed for 
long-term neurological conditions. 
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WHAT ARE ORAL SECRETIONS? 
Problems due to oral secretions are common and can be distressing in a number of 
neurological conditions. Oral secretion related symptoms can result from saliva, which may 
vary in consistency from thin and watery to thick and tenacious; but may also be caused by 
secretions originating in the nose, throat or lungs.
1
 The picture is often mixed and a range of 
treatments are required. For example, muscle weakness in the face leading to poor lip seal 
may cause problems with drooling but with evaporation from the mouth leading to 
thickened saliva from the outset. Alternatively thick secretions may occur as a direct 
result/side effect of the treatments given for managing sialorrhoea. These situations can 
make management complex, but the aim should be to achieve a balance of symptom 
control which best improves the quality of life for the patient.  
The production of oral secretions 
Saliva is produced by six major salivary glands and several hundred minor salivary glands.  
The major salivary glands are responsible for the production of approximately 90% of the 
1.5L of saliva that is produced each day. In healthy individuals the rate of swallowing as a 
result of pooling saliva is approximately once a minute, although this is variable depending 
on the rate of salivary production.
2
 The submandibular and sublingual salivary glands are 
primarily responsible for producing background saliva throughout the day, whilst the 
parotid glands primary function is to secrete saliva during periods of olfactory, gustatory 
and tactile stimulation.
3
 The parotid and submandibular salivary glands are relatively 
superficial. These differences in salivary gland function may be clinically significant as 
determiniŶŐƚŚĞƚŝŵŝŶŐŽĨĂƉĂƚŝĞŶƚ ?ƐƐĂůŝǀĂƉƌŽďůĞŵŵĂǇĂůůŽǁƚĂƌŐĞƚĞĚƚŚĞƌĂƉǇ ? Neural 
stimulation of salivary production is parasympathetic, and contraction of salivary duct 
smooth muscle is stimulated by the sympathetic nervous system. Stimulation of beta-
adrenergic receptors is responsible for the production of mucoid secretions. Oral secretions 
have several important physiological functions. Saliva protects oral tissue, lubricates food 
for swallowing and contributes to the maintenance of good dental health. Saliva and mucoid 
secretions ĨŽƌŵĂǀŝƚĂůƉĂƌƚŽĨĂƉĂƚŝĞŶƚ ?ƐďĂƌƌŝĞƌŝŵŵƵŶĞsystem.4  
Sialorrhoea and its symptoms 
Sialorrhoea is an inconsistently used term most commonly used to describe excessive serous 
saliva in the mouth which can result from hyper-secretion of saliva, anatomical 
abnormalities, or facial-bulbar weakness. In neurological conditions the aetiology of this 
r 
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excessive saliva is weakness or poor coordination of bulbar or facial musculature. This 
results in ineffective swallowing mechanics, reduced swallowing frequency,  poor lip seal 
and ineffective saliva control, but not excessive production of saliva.
1,5,6
 Sialorrhoea 
commonly affects adults with a variety of neurological conditions including: stroke; 
neuromuscular diseases such as amyotrophic lateral sclerosis (ALS) / motor neurone disease 
(MND); ĂŶĚŶĞƵƌŽĚĞŐĞŶĞƌĂƚŝǀĞĚŝƐĞĂƐĞƐƐƵĐŚĂƐWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ (PD), multiple system 
atrophy, progressive supranuclear palsy, and Lewy Body dementia. Whilst it is often stated 
that autŽŶŽŵŝĐĚǇƐĨƵŶĐƚŝŽŶŝŶWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞĐĂƵƐĞƐŚǇƉĞƌƐĂůŝǀĂƚŝŽŶĐŽŶƚƌŝďƵƚŝŶŐƚŽ
the sialorrhea, studies into salivary production in PD show reduced or normal salivation 
compared to controls.
5,7
  
Estimates of the prevalence of sialorrhoea in those neurological conditions most commonly 
associated with this symptoms are as follows; PD 10-84%;
5
 MND 20- 40%;
8
 and cerebral 
palsy 20%-58%.
9,10
  
Physical consequences of sialorrhoea include excoriation of the skin around the mouth, 
speech and sleep disturbance, dehydration, and increasing fatigue. These physical problems 
are also associated with psychosocial symptoms such as embarrassment and social 
withdrawal.
11
 In many patients with neurological disease these symptoms will be 
accentuated by muscle weakness or dystonia in the neck, trunk or limbs causing a flexed 
posture and/or difficulties maintaining oral hygiene.  Saliva may also pool at the back of the 
throat, causing coughing and a higher risk of aspiration.
12
 There are reports of pooling of 
saůŝǀĂĂĨĨĞĐƚŝŶŐƉĂƚŝĞŶƚ ?ƐĂďŝůŝƚǇƚŽƵƐĞnon-invasive ventilation (NIV), which in 
neuromuscular diseases  ? particularly MND  ? is an intervention which improves quality of 
life and survival.
13
 
Tenacious saliva and thick secretions 
The burden of problematic thickened secretions is also poorly defined. It is important to 
recognise that patients with sialorrhoea may also have thickened secretions collecting in 
their mouth and throat, often as a consequence of treatments for sialorrhoea. Thick 
secretions can lead chewing and swallowing problems and can also impact on the tolerance 
of NIV.
14,15
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ASSESSMENT OF ORAL SECRETIONS 
Areas that are important to clarify include:  
1. Evaluating the type of secretions the patient is suffering from i.e. sialorrhoea, thick 
secretions, or both; consider the impact of saliva collecting at the back of the oral 
cavity. 
2. The cause of the symptoms i.e. does the patient have dysphagia, poor lip seal, 
learning difficulties, and is there any possibility the patient has anatomical 
abnormalities or salivary hyper-secretion.  
3. The timing of the problem. Whilst unstudied, physiology suggests that if a patient 
was suffering from symptoms throughout the day, then the targeted therapies such 
as botulinum toxin and radiotherapy may need to include the submandibular gland, 
whilst if they had symptoms mainly when eating or drinking, treatment of the 
parotid glands may be more successful. 
4. Whether secretions are impacting on the ability to use non-invasive ventilation.  
5. What steps have already been taking to try and manage the problem and what other 
medication are they on. 
Multiple methods of systematically evaluating oral secretions have been used or proposed. 
Quantitative measures such as weighing cotton rolls and collection cups are largely 
impractical but can assess reductions in salivary flow. However, such assessments correlate 
poorly with subjective symptom improvement and so are of little use in clinical practice.
16
 
There are a number of patient reported and observer reported symptom rating scales. Most 
of these focus on drooling, but some have proposed including questions assessing other 
sialorrhoea related symptoms, subjective impact on other aspects of life, and concurrent 
thick secretion problems.
17,18,19
 This lack of an effective or uniform outcome measure for 
evaluating oral secretion problems is a significant barrier to the generation of good 
evidence.  
MANAGING SIALORRHOEA 
A multi-disciplinary approach should be taken; conservative measures such as suction; drug 
therapy most commonly with anticholinergics; repeated Botulinum toxin injections; 
radiotherapy and surgical interventions; have all been used to manage sialorrhoea (Table 1). 
No one treatment modality will be successful for every patient and so a combination of 
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approaches is required, undertaken in a stepwise fashion (Figure 1).5,11,20,21 Moreover, 
patients with different underlying diseases may benefit from different interventions. 
Notably, sialorrhoea in patients with Parkinson's disease usually occurs during 'off' periods 
of symptom control. Consequently the most important first step is to optimise dopaminergic 
therapy to optimise swallowing function.
5
 
Table 1: Summary of treatment options 
Type of therapy Benefits of this 
approach 
Side effects Additional info 
Conservative 
measures 
Largely cheap  
Simple 
Minimal side effects 
Few Consider these in all 
patients 
Anticholinergics Easy to prescribe 
Cheap 
Urinary retention, 
blurred vision, 
confusion 
Caution in 
myasthenia gravis 
related drooling 
Botulinum Toxin Targeted therapy Excessively dry mouth 
 
Concerns over effects 
on bulbar function 
Radiotherapy Targeted therapy Excessively dry mouth 
Risk of malignancy  
 
Effects (including 
adverse effects) last 
months to years 
Surgery Long term symptom 
relief if effective 
Generic surgical and 
anaesthetic risks 
Retention cysts 
Irreversible 
Patients may be too 
frail to tolerate  
Conservative measures 
Although there is little evidence confirming their effect, a variety of conservative measures 
for managing sialorrhoea and associated symptoms are available. The appropriate use of 
these conservative managements will vary from patient to patient.  
Neck collars and head back wheelchairs are useful devices to improve positioning and 
counteract a flexed posture. This simple measure is likely to improve patients ? comfort and 
self-image.  Speech therapy should be involved at an early stage with the aim to maximise 
the patients swallowing function and lip seal. Oral prostheses have been trialled in 
neurologically impaired patients to improve lip seal and have been shown to improve 
quality of life.
22
 For patients with WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?reduced oral sensation or CP, swallow 
reminders may be of help.
6
  
A number of oro-rehabilitation approaches have also been used in neurologically and 
cognitively impaired children with success. These include oro-motor therapy, biofeedback or 
behavioural interventions.
23
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Portable suction devices can be considered in patients with treatment resistant symptoms, 
particularly if they are suffering from pooling of saliva in the throat. Whilst these devices are 
portable they are not necessarily discrete and patients may find using them embarrassing 
(Figure 2).  
Anticholinergics 
Anticholinergics are a group of drugs which inhibit the action of the neurotransmitter 
acetylcholine at muscarinic receptors, thus reducing saliva production. Care must be taken 
when using anticholinergics not to cause an excessively dry mouth. This may be more 
distressing for the patient than their original problem and can contribute to poor oral 
hygeine.
24,25
 There are a variety of anticholinergics and drugs with anticholinergic effects 
which are used to manage sialorrhoea, including hyoscine hydrobromide, atropine, 
glycopyrrolate, tropicaimide, hycosamine sulphate  and the tricylcic antidepressant 
amitriptyline (Table 2).
5,20,26
 However, evidence supporting these drugs as effective 
interventions is limited, with only a few studies carried out across a range of diseases. 
27
 
Table 2: Example anticholinergics used to treat sialorrhoea 
Name of 
Anticholinergic 
Preparation Dose Specific characteristics and cautions  
Hyoscine 
Hydrobromide 
Trans-dermal 
patch 
0.5mg 
patch per 
72 hours 
Associated with a skin reaction at the site 
of the patch. Frequently altering the patch 
site and using topically applied steroid may 
improve tolerance. 
28
 
Glycopyrronium Tablet 
Oral solution 
(trialled in 
children) 
1 ?2 mg 3 
times/d 
Glycopyrronium has a quaternary 
ammonium structure which renders it less 
permeable to the blood brain barrier. 
Consequently it is likely to be less 
associated with CNS side effects 
29 ?
33
 
 
Amitriptyline Tablet 
 
10 ?50 mg 
at 
bedtime 
Amitriptyline has a number of other effects 
which may be exploited. 
 These include sedative and antidepressant 
effects. However the antidepressant dose 
is much higher than that typically used to 
treat sialorrhoea. 
33
 
Atropine  
 
0.5% Eye 
drops 
1 ?2 drops 
sublingual
ly 
QDS -6/d 
Can be useful if related to meals as it can 
be administered when the problem occurs. 
34, 
35
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Unfortunately, these medications are not specific to the muscarinic receptors of the salivary 
glands.
25
 Patients using these medications for sialorrhoea management are at risk of 
unwanted effects in other organ tissues. These effects include urinary retention, 
constipation, increased intra-ocular pressure, cessation of perspiration and increased body 
temperature and double vision. Moreover, anticholinergics can affect the CNS causing 
adverse effects such as confusion, disorientation, memory problems, sedation and nausea 
which can often be intolerable, especially in the elderly.
24,25
 The topically applied hyoscine 
patch can also cause skin irritation which is often severe enough to cause discontinuation.
28
  
WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ and anticholinergics 
It is important to note that there are a set of circumstances relating to Parkinson's disease 
(PD) that require significant caution when prescribing anticholinergics. Firstly, many patients 
with PD have autonomic dysfunction and so will be extremely sensitive to the unwanted 
effects of these drugs on other organs, for example the bladder. Moreover, patients with PD 
- particularly in its later stages - suffer from cognitive impairment and so may be more likely 
to become confused when using these drugs. There is also a concern that anticholinergics 
can cause Tau related pathology and ŝŶĐƌĞĂƐĞĚůǌŚĞŝŵĞƌ ?ƐƉĂƚŚŽůŽŐǇŝŶƉĂƚŝĞŶƚƐǁŝƚŚW.36 
Glycopyrronium has a structure which means it does not cross the blood brain barrier; it ?Ɛ
use as an oral solution has been trialled in 23 PD patients, showing symptomatic 
improvement and a good side effect profile.
30
 More research is required to determine the 
appropriateness of anticholinergics in this population and for the reasons outlined above, 
consideration of botulinum toxin injections at an earlier stage may be appropriate. 
Dosing regimes 
The optimal doses and delivery mechanisms for these treatments have not been identified, 
however with a high risk of side effects the approach should be to start at a low dose and 
titrate up as required and tolerated.  
Botulinum toxin 
Botulinum toxin is a neurotoxin produced by the bacteria clostridium botulinum. It has been 
used since the 1980s to treat conditions such as strabismus and dystonia. There are 7 types 
(A-G) which work by penetrating the axon terminals and degrading SNAP-25 t-SNARE 
proteins, preventing neuro-secretary vesicles fusion with the nerve synapse plasma 
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membrane.
37,38
 Both Botulinum toxin A and B have been used to manage sialorrhoea (Table 
3).
39
  
Table 3: A summary of botulinum toxin for the management of sialorrhoea 
Toxin Types 
 
Due to multiple Type A botulinum toxin subtypes, direct comparisons 
between the effects of Type A and Type B toxins are difficult. For the 
indication of sialorrhoea the comparative dose is approximately Botox® 1: 
10 botulinum toxin B.
40
 
 
 Type A  
x There are subtypes of Type A 
botulinum toxin, two of which 
(Botox® and Dysport) are 
commonly used to treat 
sialorrhoea. These subtypes 
have different biological 
activity, thus dose adjustments 
must be made accordingly 
(Botox® 1:3 Dysport).
40
 
Type B (Neurobloc) 
x Has a greater propensity for 
autonomic effects.
40
  
x Has a higher immunogenicity and 
so repeated use may have a 
greater risk of antibody induced 
failure.
41 ?43
 
Dosing x Commonly used doses in trials to date 100MU of Botox®; 250MU of 
Dysport®; 2500MU of Neurobloc.  
x Doses should be divided between the Submandibular and Parotid 
glands, with the latter receiving a greater fraction of the total dose. 
x Optimal therapeutic dose not established. Titrate as appropriate. 
44
 
Delivery US guidance   
x Confirms accurate delivery of the 
toxin 
Landmark guided  
x Practical and largely 
considered safe (Figure 3) 
Outcomes of 
treatment 
with 
botulinum 
toxin 
 
Benefits 
44
 
x Meta-analysis data supporting its 
clinical efficacy 
x Effective in patients with 
symptoms resistant to 
medications 
x Effects last for 3-6 months 
x Fewer side effects than 
anticholinergic medication 
x Minimally invasive 
x May decrease risk of aspiration 
pneumonia in neurologically 
impaired children.
45
 
 
Negatives 
x Common adverse effects: 
xerostomia, thickened 
bronchial secretions and 
viscous saliva, difficulty 
chewing and pain at the site of 
injection. Reverse slowly as 
toxin effect wears off. 
46
 
x Dysphagia may be a rare side 
effect.
47
 
x Repeat injections may result in 
antibody formation and fading 
efficacy.
43
 
 
Group 
characteristics 
 
x MND patients may be more prone to adverse effects and shorter 
benefit duration compared to the PD patients 
x Old age may be associated with longer benefit duration. 
48
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Radiotherapy  
External beam radiotherapy using photons or electrons is an alternative method for 
controlling sialorrhoea. It is a treatment modality that is usually employed following the 
failure to respond to or tolerate treatment with anticholinergic drugs and botulinum toxin. A 
number of retrospective and prospective studies exist, carried out in patients with PD and 
MND, reporting objective reductions in saliva production and improvements in subjective 
patient symptoms.
49
 Whilst these studies did not include control groups, the same patients 
had previously failed to achieve symptomatic control with other available treatments for 
sialorrhoea.  As with botulinum toxin injections, there is no consensus about the optimal 
dosing regimen for salivary gland irradiation to treat sialorrhoea. Most commonly regimes 
target both submandibular glands and the caudal two thirds of both parotid glands. Studies 
to date have used a range of doses, with a median dose per fraction of 5Gy (0.83-8) and a 
mean total dose of 12Gy (3-48). The length of effect of radiotherapy is variable and was 
reported to last for several months to 5 years, with around 50% of patients still experiencing 
effects at 6 months.   
Radiotoxicity can occur resulting in an overly dry mouth with more viscous saliva, facial 
erythema, pain and nausea.
49
 These effects are usually short lived and the risk of their 
development is likely to be reduced with the development of new techniques, such as CT 
mapping which allows for highly localised therapy 
50
. Because of the short life expectancy of 
many of the patients with neurological disease there is less concern about malignancy, 
however in those with longer life expectancy this may be an unnecessary risk.  
Surgical Options 
Effective surgical interventions for sialorrhoea do exist. Options include the removal of the 
submandibular or parotids salivary glands, submandibular and/or parotid duct relocation or 
ligation, and transtympanic neurectomy.
51
 These surgical interventions have most 
commonly been used in neurologically impaired children with symptoms resistant to 
medication and botulinum toxin. The use of surgery to manage sialorrhoea in older patients 
is rare and would only be considered after failure of less invasive approaches.  
 11 
Meta analysis of surgical options suggests that bilateral submandibular duct rerouting, 
bilateral submandibular gland SMG excision with bilateral parotid duct rerouting, and 
bilateral SMG excision with bilateral parotid duct ligation appear to be of similar efficacy.
51
 
Whilst potentially less effective, four duct ligation offers a simple, quick and safe procedure 
which may improve symptoms.
52
   
Amongst patients with MND, PD and other neuromuscular and neurodegenerative disorders 
many will not have the functional reserve to tolerate surgical intervention. Additionally, life 
expectancy is often short and so there is less need for interventions that will work for many 
years.  
 
MANAGEMENT FOR THICK SECRETIONS 
Symptoms related to thickened secretions often are difficult to manage, with the available 
treatment options more limited than those for sialorrhoea. If a patient is distressed by 
thickened secretions that are likely to be a result of treatment for sialorrhoea then titrating 
down to the smallest effective dose can be helpful. Discussions with the patients and carers 
about which of these opposing secretion problems is more troublesome will help achieve 
the best balance for the patient. 
There are a number of options for alleviating the discomfort associated with thickened 
saliva, many of which are conservative. Simple approaches include checking the patient ?s 
fluid intake, thinning secretions with juices and ice cubes - grape, apple, pineapple or 
papaya or frequent swabbing of the mouth. The use of a mouthwash of one teaspoon 
bicarbonate of soda or one teaspoon salt in a glass of water after meals can also be helpful. 
Mucolytic agents such as N-acetyl cysteine and carbocisteine are effective and commonly 
used.
53
 A pilot study in 1996 investigated the use of beta-blockers in the management of 
thick mucoid saliva with promising results, but to date there appears not to have been any 
confirmatory studies.
1
  
In patients with more problematic symptoms other measures include nebulised saline to 
loosen and thin secretions, or using suction pumps and assisted cough techniques to 
remove secretions.
53
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FIGURE LEGEND: 
Figure 1: A suggested generic management approach to a patient with symptoms relating to oral 
secretions. This management approach is derived from expert clinician experience 
Figure 2: Portable suction unit 
Figure 3: Delivering botulinum toxin Injections by landmark guidance 
4
. Image A ʹ Locating the 
parotid gland: Find the mid-point on the line connecting the tragus to the angle of the mandible, 
approximately the site of the ear lobe. Deliver injection 1cm anterior to this site. Image B ʹ Locating 
the submandibular gland: Find the mid-point between the angle of the mandible and the tip of the 
chin. Inject 1 finger breadth medial to the inferior surface of the mandible at this point. Direct 
needle straight upwards, staying as close to the medial surface of the mandible as possible. NOTE: 
ĚĂƉƚĞĚĨƌŽŵŝŵĂŐĞŝŶ ‘^ƌŝǀĂŶŝƚĐŚĂƉŽŽŵW ?WĂŶĚĞǇ^ ?,ĂůůĞƚƚD ?ƌŽŽůŝŶŐŝŶWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ PĂ
ƌĞǀŝĞǁ ?WĂƌŬŝŶƐŽŶŝƐŵZĞůĂƚŝƐŽƌĚ ? ? ? ? ? ? 
 
